| Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study Data Collection on Adverse Events of Anti-HIV Drugs Study Group Archives of internal medicine 166 (15), 1632-1641, 2006 | 1501 | 2006 |
| Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration D: A: D Study Group The Lancet 371 (9622), 1417-1426, 2008 | 1174 | 2008 |
| Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies A Trickey, MT May, JJ Vehreschild, N Obel, MJ Gill, HM Crane, ... The lancet HIV 4 (8), e349-e356, 2017 | 1116 | 2017 |
| Cognitive dysfunction in HIV patients despite long-standing suppression of viremia S Simioni, M Cavassini, JM Annoni, AR Abraham, I Bourquin, V Schiffer, ... Aids 24 (9), 1243-1250, 2010 | 901 | 2010 |
| Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study B Hasse, B Ledergerber, H Furrer, M Battegay, B Hirschel, M Cavassini, ... Clinical infectious diseases 53 (11), 1130-1139, 2011 | 751 | 2011 |
| Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1133-1144, 2008 | 578 | 2008 |
| Decreasing mortality and changing patterns of causes of death in the S wiss HIV C ohort S tudy R Weber, M Ruppik, M Rickenbach, A Spörri, H Furrer, M Battegay, ... HIV medicine 14 (4), 195-207, 2013 | 493 | 2013 |
| Dominant TNF-α+Mycobacterium tuberculosis–specific CD4+ T cell responses discriminate between latent infection and active disease A Harari, V Rozot, FB Enders, M Perreau, JM Stalder, LP Nicod, ... Nature medicine 17 (3), 372-376, 2011 | 489 | 2011 |
| PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals R Banga, FA Procopio, A Noto, G Pollakis, M Cavassini, K Ohmiti, ... Nature medicine 22 (7), 754-761, 2016 | 476 | 2016 |
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ... European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010 | 445 | 2010 |
| characteristics, determinants, and clinical relevance of CD4 T cell recovery to< 500 cells/µL in HIV type 1—infected individuals receiving potent antiretroviral therapy GR Kaufmann, H Furrer, B Ledergerber, L Perrin, M Opravil, P Vernazza, ... Clinical infectious diseases 41 (3), 361-372, 2005 | 436 | 2005 |
| Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active … A Mills, JR Arribas, J Andrade-Villanueva, G DiPerri, J Van Lunzen, ... The Lancet Infectious Diseases 16 (1), 43-52, 2016 | 367 | 2016 |
| Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV Cohort Study S Franceschi, M Lise, GM Clifford, M Rickenbach, F Levi, M Maspoli, ... British journal of cancer 103 (3), 416-422, 2010 | 357 | 2010 |
| Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study B Ledergerber, H Furrer, M Rickenbach, R Lehmann, L Elzi, B Hirschel, ... Clinical Infectious Diseases 45 (1), 111-119, 2007 | 324 | 2007 |
| Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV‐infected Individuals M Rotger, H Tegude, S Colombo, M Cavassini, H Furrer, L Decosterd, ... Clinical pharmacology & therapeutics 81 (4), 557-566, 2007 | 321 | 2007 |
| Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America M Helleberg, MT May, SM Ingle, F Dabis, P Reiss, G Fätkenheuer, ... Aids 29 (2), 221-229, 2015 | 299 | 2015 |
| Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral … FA Post, GJ Moyle, HJ Stellbrink, P Domingo, D Podzamczer, M Fisher, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 55 (1), 49-57, 2010 | 290 | 2010 |
| CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial J Ananworanich, A Gayet-Ageron, M Le Braz, W Prasithsirikul, ... The Lancet 368 (9534), 459-465, 2006 | 288 | 2006 |
| Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America Antiretroviral Therapy Cohort Collaboration Clinical Infectious Diseases 41 (12), 1772-1782, 2005 | 285 | 2005 |
| Evaluation of MRSA-Screen, a Simple Anti-PBP 2a Slide Latex Agglutination Kit, for Rapid Detection of Methicillin Resistance in Staphylococcus aureus M Cavassini, A Wenger, K Jaton, DS Blanc, J Bille Journal of Clinical Microbiology 37 (5), 1591-1594, 1999 | 280 | 1999 |
